

Roadshow Presentation

MARCH 2025

Clayton Astles
Chief Executive Officer

Brendan MaherChief Financial Officer





1HFY25 Financial Summary: Record Performance

62%

150%

Revenue Growth

Successful integration of acquisitions drove record \$36.9M

EBITDA Increase

Reached \$5.2M, exceeding top end of guidance

270%

15%

NPBT Growth

\$3.9M profit, up \$2.9M from previous period

Software Growth

Software and SMA revenues reached \$4.6M

Our M&A Strategy: Driving Growth Through Strategic Acquisitions

Our acquisition strategy targets three key areas: systems integrators, technology companies, and strategic competitors to enhance capabilities, fill product gaps, and strengthen market position.

1

2

3

Systems Integrators

Expands our implementation capabilities. Enhances our service offerings to deliver comprehensive solutions.

Technology Acquisitions

Fills critical product gaps. Accelerates our innovation timeline through proven technologies.

Strategic Competitors

Strengthens our market presence. Expands our customer base in key segments.

These targeted acquisitions will drive accelerated growth, increase our market share, and enhance our competitive advantage.







Products Roadmap Vision




Tacera


Care Communications Platform





Real-Time Locating (RTLS)













•





Fall Detection & Monitoring



Pulse Insights

Live data updates for key metrics

Augments all interfaces

Explicit chart widgets and anonymous color tiles


Re-imagining of Pulse Dashboards into real-time data transfer

Step 1 for Al-informed "predictive" product














Enterprise Products



OPERATIONAL INSIGHTS


AI-Informed

Call Volume & Staffing

Unusual Call Patterns


Automatic Workflow Assignment

Must present clear ROI for customers



FALL DETECTION, MOVEMENT

Makes sense to sell with nurse call
Radar or camera-based
Over time, can predict resident needs
A nice-to-have



SYSTEM READINESS

Network,

Servers,

Device Faults,

Database Storage,

Deployment Data (for R&D)



TOUCHPOINT

>>> Less Medical, More Versatile

Extend the value of a customer's investment by offering multiple software functions on a single device


Tones and visual for out-of-the-way areas

2-way VOIP calling


Install once, configure from anywhere


Runs all touchscreen applications

Can show any piece of data, from any integrated system



















Collaboration is the future of mobile

We aim to take advantage of the unique opportunities a mobile platform offers.



- VoIP calling and secure text messaging
- 2 Share tasks, reminders, and statuses with care team members
- Create reminders for individual locations and be reminded when near that location
- Manage alarms and alerts from all clinical systems, not just nurse call






REVENUE FROM CUSTOMERS

Record revenue for the 1H25 of \$36.9 million is underpinned by the successful integration of the two recently acquired businesses (Teknocorp and Amentco who combined contributed \$11.9 million of revenue) and validates our mandate to continue to grow via the acquisition of quality businesses in our industry.

Our revenue at \$36.9 million is at the top end of our guidance issued via a trading update to the ASX on 18 December 2024.

Strong organic growth from Asia and North America also assisted in increasing revenue by 62% (\$14.1 million) on pcp, and up 5% (\$1.6 million) on 2H24.

As a result of the acquisitions, our Australian operations now represent 39% of Group revenues.




SOFTWARE AND SMAREVENUES

In addition to the strong total revenue growth, our software and SMA revenues also experienced an 15% increase to \$4.6 million over the pcp.

With little of that increase attributed to the acquired businesses we see future upside as we introduce more Software and SMA focus into those businesses.

Whilst Software and SMA revenues comprised 12.5% of group revenue in the reported period, it comprises 19.4% (\$9.7 million) of our Unfilled Contracted Revenue highlighting the vital role it will play in driving our company's future growth and success.




GROSS PROFIT AND MARGIN

As forecasted our gross margins at 51.1% experienced a reduction compared to the prior corresponding period of 51.9%, due to the newly acquired businesses being lower gross margin businesses.

This reduction in our gross margin percentage did mean that gross margin dollars were flat against 2H24 at \$18.8 million but were up \$7.0 million on the pcp.

GROSS MARGIN (\$'M)



EBITDA

EBITDA was up 150% to \$5.2 million over the pcp of \$2.1 million.


Our EBITDA at \$5.2 million was above the top end of our guidance issued via a trading update to the ASX on 18 December 2024.

The financial benefits of revenue growth drive the Company's improved EBITDA. Operating costs were up consistent with taking on the cost bases of the acquired businesses.

We continued investment in R&D, but in the reporting period we had no material M&A transaction costs.

EBITDA (\$'M)






NET PROFIT BEFORE TAX

Net Profit before Tax (NPBT) was up 270% from \$1.0 million in the pcp to \$3.9 million, highlighting the strong operating leverage of our business model as increased revenues convert into strong profit growth.

REPORTED NPBT (\$'M)




\$5M

CASH

Cash was \$14.9 million at 31 December 2024 (including \$5.7 million held in Term Deposits), up \$1.3 million from June 2024. Austco Healthcare is debt-free.

Cash generated from operating activities of \$2.2 million has allowed for our expanded working capital needs.





Tariff Impact Assessment: Limited Exposure

Only US Shipments from China Affected

Austco Healthcare drop ships from Hong Kong to all regions. The impact is limited to goods shipped into the United States from China, which accounts for 18% of group revenues. US Tariffs have been passed on to our customers through price list adjustments.

No Canada/Mexico Impact

Direct shipping avoids cross-border tariffs. Austco Healthcare does not ship products between the US, Canada and Mexico.


Proactive Shipments

Austco brought forward shipping of goods to our US office to avoid additional tariffs recently introduced for Chinese imports.





With a clear strategic vision and a commitment to innovation,
Austco Healthcare is positioned for meaningful growth for the foreseeable future.



STRONG FINANCIAL PERFORMANCE

Record revenues of \$36.9 million and EBITDA of \$5.2 million were delivered in the first half of FY25. We are focused on maximizing revenue streams to drive profitability and long-term value for our shareholders.

INNOVATION

We will continue to prioritise innovation and product development, investing in the development of solutions that address the evolving needs of healthcare organisations worldwide.

SOFTWARE & SMA REVENUE

Increased interest in high-margin workflow and software solutions. Software and SMA revenues will play a vital role in driving the Company's future growth.

MERGERS AND ACQUISITIONS

By strategically integrating complementary businesses, technologies, and talent, we will strengthen our competitive edge and drive sustainable growth





CLAYTON ASTLES

CEO & Executive Director Aust: +61 411 531 170 US: +1 682 803 1222

clayton.astles@austco.com



BRENDAN MAHER

CFO & Company Secretary
Aust: +61 439 369 551
brendan.maher@austco.com



DISCLAIMER

- •This presentation was prepared by Austco Healthcare Limited and was authorised for release by the Board of the Company.
- •This publication does not constitute an offer, invitation or recommendation for the sale or purchase of any securities in any jurisdiction.
- •References to, and the explanation of, legislation and regulatory issues in this Publication are indicative only and should not be relied on. They do not purport to summarise all relevant legislation and regulatory issues or to be a full explanation of any particular matter.

Past Performance

•Past performance information given in this Publication is given for illustrative purposes and should not be relied upon as an indication of future performance.

Forward Looking Statements

•The information contained herein involves elements of subjective judgment and analysis and may be identified by words such as 'may', 'could', 'believes', 'expects', 'intends' or other words that involve risk and uncertainty (collectively, forward looking statements). Any forward looking statements expressed in this Publication are subject to change without notice. They do not constitute, and should not be regarded as, a representation that the relevant results will actually be achieved or that the underlying assumptions upon which forward looking statements may be based are valid or reasonable. Actual results may vary from the forward looking statements and such variations may be material.

Other Information

•All financial amounts contained in this Publication are expressed in Australian currency unless otherwise stated. Any discrepancies between totals and sums and components in tables contained in this Publication are due to rounding.

Disclaimer

•Other than to the extent required by law, neither Austco nor any of their

- •respective affiliates, associates, shareholders, directors, officers, employees, agents, representatives and advisers (the Austco Parties) make any representation or warranty (express or implied) as to, and assume responsibility or liability for, the authenticity, origin, validity, accuracy or completeness of, or any errors in or omissions from, any information, statement or opinion contained in this Publication or in any accompanying, previous or subsequent material or presentation in connection with the subject matter of this Publication.
- •Without limiting the foregoing, none of the Austco Parties:
- •• makes or purports to make any statement or representation (including, but not limited to, any representation with respect to any forward looking statement) contained in this Publication;
- •• is responsible for the contents of this Publication;
- has verified the accuracy or completeness of this Publication; or
- •• is liable in any way for any misstatement in, or errors in or omission from, this Publication or in any accompanying, previous or subsequent material or presentation in connection with the subject matter of this Publication, except and then only to the extent required by law.

United States

- •In particular, this Publication is not an offer of securities for sale in the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the United States Securities Act of 1933 (the Securities Act)). Austco, its affiliates and related bodies corporate are not and will be registering any securities under the Securities Act or the securities laws of any state of the United States or any other jurisdiction other than the Commonwealth of Australia.
- •This document has been prepared for publication in Australia and may not be released or distributed in the United States or to U.S. persons. Failure to comply with this directive may result in a violation of the Securities Act and/or another applicable law of the United States or another jurisdiction.